DNA, CRA and Applera are each ADC licensees.
Press Release Source: Celera Genomics Group
Celera Genomics Announces Oncology Collaboration Agreement with Genentech
Tuesday September 28, 7:00 am ET
ROCKVILLE, Md.--(BUSINESS WIRE)--Sept. 28, 2004--Celera Genomics Group (NYSE:CRA - News), an Applera Corporation business, today announced a collaboration with Genentech, Inc. (NYSE:DNA - News) to discover and develop targeted therapies for cancer. Genentech may develop various products against therapeutic targets licensed from Celera, including antibodies, antibody fragments, proteins or small molecule drugs.
Under the terms of the multi-year agreement, Celera Genomics will nominate a number of cell-surface antigens discovered and validated through its proprietary proteomic platform as potential therapeutic targets. Any of these antigens may be designated by Genentech for further validation and research to identify therapeutics for subsequent development solely by Genentech. Genentech shall make progress-dependent milestone payments to Celera Genomics, based on achievement of preclinical, clinical and commercial milestones, and shall pay royalties on net sales of any resulting therapeutic products. Celera Diagnostics, a joint venture between Celera Genomics and the Applied Biosystems Group (NYSE:ABI - News) of Applera, retains certain diagnostic rights associated with the designated targets.
"We are pleased to partner with Genentech, an established global leader in antibody technology and oncology," said Kathy Ordonez, President, Celera Genomics. "With its proven track record in the discovery, development and commercialization of novel treatments for cancer, Genentech has the expertise to develop targeted therapies against proteins that Celera has validated as potential therapeutic targets through its proteomics research."
|
